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Bone tunnel healing is an important consideration after anterior cruciate ligament (ACL) replacement surgery. Recently, a variety
of materials have been proposed for improving this healing process, including autologous bone tissue, cells, artiﬁcial proteins,
and calcium salts. Amongst these materials are calcium phosphates (CaPs), which are known for their biocompatibility and are
widely commercially available. As with the majority of the materials investigated, CaPs have been shown to advance the healing of
bone tunnel tissue in animal studies. Mechanical testing shows ﬁxation strengths to be improved, particularly by the application of
CaP-based cement in the bone tunnel. Signiﬁcantly, CaP-based cements have been shown to produce improvements comparable
to those induced by potentially more complex treatments such as biologics (including ﬁbronectin and chitin) and cultured cells.
Further investigation of CaP-based treatment in the bone tunnels during ACL replacement is therefore warranted in order to
establish what improvements in healing and resulting clinical beneﬁts may be achieved through its application.
1.Introduction
In all types of anterior cruciate ligament (ACL) reconstruc-
tion, a proportion of grafts fail due to a lack of healing in
the bone tunnel or abrasion of the graft at the tunnel exit
[1]. It has been suggested that stable bone tunnel healing is
desirable for an ACL graft to be successful [2] and that the
acceleration of the healing between a soft tissue (tendon)
graft and bone may allow earlier return to functional
activities and improve clinical outcomes [3]. Unsatisfactory
osseointegration of tendon grafts used for the replacement
of ACL may also be associated with postoperative anterior-
posterior laxity [4]. It may therefore be expected that
improvements in bone tunnel healing, including ingrowth
or ongrowth of tissue around the graft, will improve
ﬁxation strength and limit graft failures by pullout and
loosening.
Av a r i e t yo fm a t e r i a l sh a v eb e e na p p l i e di nt h eb o n e
tunnels in order to improve healing. These range from
autologous bone tissue or cells to proteins and calcium salts.
In particular, a number of studies have proposed the use
of calcium phosphate (CaP) materials for this purpose. The
application of CaP to soft tissue attachments is becoming
more common and has been shown to induce increases in
ﬁxation strengths and bone formation.
This review examines the hypothesis that the application
of CaP can improve bone tunnel ﬁxation and healing in
ACL grafts. The evidence for the usefulness of CaPs in ACL
replacement is discussed along with evidence for the eﬃcacy
of CaP in other relevant applications and other materials
used for bone tunnel healing improvement. The following
section gives a brief introduction to ACL replacement,
mechanismsofbonetunnelhealing,andmethodscommonly
used to assess healing.2 Journal of Tissue Engineering
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Figure 1: The anatomy of the bones of the knee showing the position of the bone tunnels from (a) frontal and (b) lateral views. The patella
and patellar tendons are omitted for clarity.
2. Bone TunnelHealing inACLReplacement
2.1. ACL Anatomy and Injury. The ACL is one of two liga-
ments located in the centre of the knee joint. It has insertions
in the tibia and distal femur and has a microstructure made
up of collagen bundles surrounded by a complex matrix
[5]. The ACL restricts anterior tibial translation and gives
stability in rotation. Failure to treat this type of injury may
leadtomechanicalinstabilityinthekneeandhasbeenlinked
to the early onset of osteoarthrosis [6]. Damage to the ACL
mayoccurfrombothcontactandnoncontactmechanismsof
injury [7]. It is common both in the general population and,
more particularly, in those taking part in sporting activities.
A recent study based in the United Kingdom identiﬁed the
rate of ACL injury at 8.1 instances per 100,000 people per
year [8]. Reconstructive surgery is routinely carried out for
patients with a torn or ruptured ACL. In the USA, around
200,000 ACL reconstructions are performed each year [9].
The reader is referred to recent reviews for detailed informa-
tion on ACL anatomy, function, and injury [5, 10, 11].
2.2. ACL Replacement. The ACL does not heal when torn
because it lacks suﬃcient vascularisation. Surgical recon-
struction is the standard treatment in sports medicine for
ACL rupture [5]. Patients with ACL injuries are typically
younger and more active than other orthopaedic patients,
and reconstructions should exhibit good longevity, with-
standing high stresses over millions of cycles [12]. However,
the outcomes of the various techniques used for ACL
replacement have not always been positive. Patient selection
and implantation technique have contributed to poor results
from artiﬁcial grafts, allografts, and autografts.
Over the past 10 years, technique has vastly improved,
making autograft ACL replacement both common and more
successful. The procedure is usually carried out arthroscop-
ically using a graft from the semitendinosus tendon or the
central third of the patellar tendon. In the latter case, the
graft is harvested with a section of bone at each end and
interference screws are used to ﬁx the bone plug into place.
These are known as bone-tendon-bone (BTB) grafts. A
recent review suggests that there is no signiﬁcant diﬀerence
in clinical results between autograft types, with factors other
than graft donor site (including ﬁxation, damage to the
meniscus and articular cartilage, and the requirement of
additional surgical procedures) being the most important
determinants for successful outcomes [13].
Once the graft has been harvested and prepared, often by
pretensioning and the addition of sutures, tunnels are drilled
throughthetibiaandfemurpassingthroughtheattachments
of the original ligament (see Figure 1). The graft is pulled
into position and ﬁxed using staples, screws, sutures, or
commerciallyavailableﬁxationdevicessuchasthecross-pins
or interference screws. The surgical ﬁxation is the weak point
of the graft in the early postoperative stages and remains so
until bone tunnel healing occurs [14].
Autografts for ACL replacement have limitations includ-
ing limited availability, and adverse functional changes
including muscle weakness at the donor site. Conversely,
artiﬁcial or tissue-engineered ligament grafts have some
distinct advantages. These include the ability to control
manufacturing, condition, quality, sterility and size of device
before implantation. Mechanically tested and controlled
grafts could be made available oﬀ the shelf and eliminate the
need to create a second defect site through the harvesting ofJournal of Tissue Engineering 3
healthy tissue. Unfortunately, the majority of artiﬁcial ACLs
have suﬀered from high failure rates due to mechanical, and
in some cases biological, inﬂuences and have been removed
from the market [12]. In the early postoperative stages, the
majority of these failures occurred in the bone tunnels.
2.3. Bone Tunnel Healing. The insertion of the native
ACL is characterised in four layers: tendon, ﬁbrocartilage,
mineralised ﬁbrocartilage, and bone. The collagen ﬁbres
of the tendon extend into both the ﬁbrocartilage, and the
mineralised layer. This structure is usually destroyed when
the ligament is removed and the bone tunnel is drilled. A
replication of this direct type of insertion may be considered
desirable when assessing bone tunnel healing for ACL grafts.
The mechanism by which graft-bone healing occurs
depends on the type of graft used. For BTB grafts, healing
in the tunnel resembles normal fracture healing, but may be
a more complex process. Incorporation of the bone block
in the tunnel has been observed as early as 16 weeks after
surgery [15]. BTB grafts have the advantage of allowing rigid
ﬁxation of the graft in the bone tunnel.
The tendon-bone healing process occurs through a
diﬀerent mechanism after implantation of a soft tissue graft
without bone plugs [15]. Firstly, ﬁbrovascular tissue forms
between the graft and bone and becomes mineralised. The
tendon tissue itself is then mineralised and incorporated into
the bone [16]. Sharpey’s ﬁbres are made up of type I collagen
and connect the periosteum to the bone. The formation of
Sharpey-like ﬁbres within the bone tunnel is often identiﬁed
as a marker of indirect healing between the tendon and
bone [17]. The formation of these collagenous ﬁbres may
occur from six weeks after surgery. However, complete bone
tunnel healing of an ACL graft may occur as late as six to
twelve months after surgery [15]. Some studies in animals
have suggested that tendon graft incorporation occurs more
slowly than BTB healing [2].
In addition to the choice of graft, surgical ﬁxation, and
graftposition,interfacialmotionwithinthebonetunnelmay
aﬀect healing [2]. Graft motion within the bone tunnel has
been shown to be inversely proportional to healing in an
animal model [18].
2.4. Assessment Techniques for Bone Tunnel Healing. Three
main factors are commonly assessed to evaluate bone tunnel
healing after ACL replacement: functional outcome, biologi-
cal structures, and mechanical properties. In clinical studies,
functional outcome is measured by patient satisfaction, pain
levels, and scores in the International Knee Documentation
Committee (IKDC) and Knee injury and Osteoarthritis Out-
comeScore(KOOS)tests.Inbothclinicalandanimalstudies,
the biological structures in the bone tunnel are examined
using noninvasive imaging. In animal models, these struc-
tures can also be examined by the excision and histological
examinationofthegraft-boneconstruct.Thismethodcanbe
used to identify collagen ﬁbres, calciﬁed tissue and diﬀerent
types of cell found in the bone tunnel. Imaging techniques
include the use of X-rays for the assessment of bone tunnel
width and, more recently, the use of CT scanning to quantify
the amount of bone tissue formed within the tunnels.
Biomechanical tests are carried out on the tibia-graft-
femur construct following in vivo studies in animals. This
testingyieldsstrengthandstiﬀnessdata,aswellaspermitting
observation of the mode of failure of the graft. The explanted
bone-graft construct is mounted in a tensile test machine
and, most commonly, extended to failure at a constant rate.
The ultimate tensile strength (UTS) is recorded, and graft
stiﬀness may be calculated. Direct comparison of data from
these tests is complicated by diﬀerences in angles of ﬂexion
chosen when mounting the bones for the test as well as
variations in extension rate, pretensioning or cyclical loading
of the graft and the type of animal model used. In particular,
therateofextensionmayinﬂuencethemechanicalbehaviour
of the graft [25].
Two distinct modes of failure are reported in tensile
testing. Pullout is the term commonly used to indicate a
failure of the ﬁxation or tendon-bone interface. The pullout
strength of a graft is the force required for failure to occur
by this mode. The UTS of a graft may refer to pullout or
to midsubstance failure, which describes the rupture of the
graft material itself or, in some cases, the deformation of
the graft beyond a functional length. The majority of studies
combine load-to-failure data, irrespective of the mode of
failure which occurred. It is expected that failures in the
early postoperative stages will occur in the bone tunnel, with
midsubstance failure becoming the more common mode as
bone tunnel healing advances, leaving the soft tissue graft
itself as the weakest point in the construct [14]. A diﬀerence
in the mode of failure occurring in experimental and control
groups may therefore be interpreted as an indication of
an increase in strength of the bone-graft interface, assum-
ing the bone healing enhancement does not weaken the
graft.
3. CalciumPhosphates
3.1.CalciumPhosphatesasBiomaterials. CaPsareconsidered
to be safe, biocompatible materials for use in long-term
implantation. They have been used in a variety of applica-
tions including hip stem coatings and bone graft materials
and are commercially available in injectable, powder, granu-
lar, and block forms.
CaP is bioactive: the presence of Ca and P ions allows the
formation of a direct chemical bond between the bone and
the implant [26]. The exact properties of CaPs depend on
the Ca:P ratio, the crystallinity of the material, the presence
of water and the purity of the material [27]. Hydroxyapatite
(HA) has Ca:P ratio of 1.67 and may be considered as
stoichiometric CaP. CaP occurs naturally in the body as
the mineral component of bone and enamel in a form
resembling HA [28]. β-tricalcium phosphate (β-TCP) is a
more quickly resorbed form of CaP. HA is resorbed over a
period of decades, while β-TCP resorbs in months [29]. The
adsorption of particles on the surface of CaP is related to
its crystallinity and inﬂuences the biological response to the
material. CaP powders of diﬀerent sizes have been shown
to produce diﬀering rates of bone formation in vivo [30].
The reader is referred to a review of bioceramics for more
information on general uses and properties of CaP [31].4 Journal of Tissue Engineering
Table 1: Mechanical testing of diﬀerent augmentation methods using calcium phosphates for bone tunnel healing. For ease of comparison
and where available, data from mechanical testing at six weeks after surgery are given. Results at earlier and later time points are detailed in
the text. Where six week data is not available, the nearest time period is included. aThese values were calculated from the average values in
the preceding two columns. bReﬂects a diﬀerence in the predominant mode of failure from pullout failure in the controls to midsubstance
failure in the treated subjects. cThis is a low-porosity CaP control, not a nontreated sample.
Augmentation method
Average increase
in strength (as %
of control)a
Ultimate tensile
strength in
treated group
Ultimate tensile
strength in
control group
Change in mode
of failureb Time (weeks) Reference
Brushite calcium phosphate
cement (CPC) 118% 94±42 N 43±11N  6[ 19]
Injectable tricalcium
phosphate cement (TCP) 87% 62.90±7.62 N 33.60±5.87N  4[ 20]
Injectable CaP cement 110% 11.491±2.865 N 5.253±3.955N × 2[ 21]
Injectable CaP
with magnesium 65% 71.8±31.8 N 43.4±14.8N × 6[ 22]
Hybridization by
CaP precipitation
Not statistically
signiﬁcant 116.9±48.3 N 109.4±47.2N
2/7 failed by pullout
in treated group, 3/7
in control
6[ 23]
Bulk CaP with
interconnected pores 116% 12.8±5.9 N 5.0±1.8 Nc × 6[ 24]
In this review, CaP is employed as a general term for
calcium phosphate-based materials and is used where the
speciﬁctypeofCaPisnotidentiﬁedintheoriginalstudy.The
speciﬁc type of CaP produced or used in a study is identiﬁed
when possible.
The following section is a review of studies using
CaP to improve bone tunnel healing. Both qualitative and
quantitative assessments are considered, along with analysis
of biomechanical changes induced by the treatments. A
summary of the outcomes of mechanical testing from these
studies is given in Table 1.
3.2. Calcium Phosphates in ACL Reconstruction
3.2.1. Injectable Materials. A short-term biomechanical
study on the eﬀects of CaP cement on the pullout strengths
of tendon grafts for ACL replacement was carried out using
a rabbit model by Tien et al. [21]. Grafts were implanted
bilaterally and held in place with sutures. One graft in
each subject was then further ﬁxed in place by injection of
the bone cement into the tunnel. The application of the
cement led to increase in pullout strength, with the average
strength more than doubled as measured two weeks after
surgery. Biomechanical testing was not carried out at later
time points. Histological examination showed bone islands
growing between the cement, bone and tendon as early as
three weeks after implantation. Bone development extended
to 24 weeks after surgery. In the noncemented control
subjects, no bone formation was found in the interfacial gap.
These ﬁndings are supported by Huangfu and Zhao,
who examined the use of injectable resorbable TCP in bone
tunnels in a canine model [20]. The grafts ﬁlled only the
articular ends of the tunnels and were ﬁxed using sutures.
The CaP was then used to ﬁll the sections of the tunnels not
ﬁlled with the graft. Although the TCP was not speciﬁcally
injected into the tendon-bone interface, it was observed
to be present in that area during histological evaluations.
At 12 weeks after implantation, in the experimental grafts,
areas resembling a normal ACL insertion appearance with
ﬁbrocartilageandcalciﬁedbonewerepresent.Theremainder
of the interface showed a regular Sharpey-like ﬁbre link
from tendon to bone. Bone development in the controls was
found to be slower, with no calciﬁed tissue or ﬁbrocartilage
formed. The pullout strength of the grafts was found to be
increased by the presence of the TCP up to six weeks after
surgery. While earlier results were statistically signiﬁcant,
the signiﬁcance of data gathered at the six week time point
was limited by the size of the sample. From eight weeks
after surgery, all failures in the test group occurred by mid-
substance rupture. This study established a clear pattern of
improved intratunnel healing up to 12-weeks after surgery.
The authors of these studies do not discuss whether
the observed improvement in healing was the result of the
restriction of graft movement in the tunnel due to the
presence of the cement or of increased bioactivity due to the
chemical eﬀect of the CaP. Huangfu and Zhao do, however,
speculate that the use of a resorbable material is preferable if
a normal ligament-bone insertion is to be developed [20].
In a further study examining the eﬀects of CaP-based
cements,acementcontaining brushite (dicalciumphosphate
dihydrate) was shown to increase ﬁxation strengths in ACL
grafts up to 12 weeks after implantation in a rabbit model
[32]. The increase in strength was 118% six weeks after
surgery and 55% at the 12 week time point. The cement was
injected into the bone tunnels before the grafts were pulled
into place. In vivo, the cement degraded to leave granules
of β tricalcium phosphate between the bone and tendon.
The majority of failures in the treated group occurred in
the intra-articular section of the graft, whereas control grafts
failed by pullout. The increase in strength correspondedJournal of Tissue Engineering 5
with larger amounts of bone formation around the tendon
graft.
Gulotta et al. investigated the use of an alternative to
standard injectable CaP materials by adding magnesium to
the cement [22, 33]. While standard CaP cements act as
grout, ﬁlling the space between the bone cavity and the graft,
theinclusionofmagnesiumwasintendedtogivethisproduct
adhesive properties. The study was carried out in a rabbit
model, and grafts were held in place using sutures. In the
control group, no cement or adhesive was applied. Three
weeks after surgery, the strength of the experimental group
was the same as that of the controls. However, this may have
resulted from incomplete hardening of the adhesive at this
stage. Six weeks after surgery failure loads were 65% higher
than the controls. The failure of the grafts is described as
occurring at the “graft-tunnel junction.” The authors note
that although the graft ﬁxation strength was increased in
this study, it did not achieve the strength of an unoperated
tendon. The average ultimate load-to-failure of the native
rabbit ACL has been shown in a previous study to be
351.8±41.6N (Labs 2002 cited by [22]), while mean load
to failure in the treated group was 71.7N [22]. This study
also made use of μCT scanning to quantitatively measure
the increase in bone volume in the tunnels. A signiﬁcant
increase in total intratunnel bone volume was observed in
the experimental group when compared to control at six
weeks. Staining also showed more cartilage tissue and less
ﬁbrous tissue formation in the bone tunnels. The increase in
cartilage formation was shown to be statistically signiﬁcant
at six weeks after surgery, as evidenced by an increased area
of metachromasia (79556.2±61664.0μm2 compared with
2806.2±6 873.7μm2 for the control) [22].
Although the results of this study show improvement
when compared to controls in which no bone adhesive was
used, the role of the magnesium in this improvement has
not been proven. When comparing the results of this study
to others using CaP cements, there does not appear to be
an increase in strength corresponding to the presence of the
magnesium (see Table 1).
It is important to note that the use of bone cements in
ACL graft attachment without additional surgical ﬁxation
has been shown to result in inadequate ﬁxation [34]. An in
vitro study in porcine bone compared various methods of
surgical ﬁxation, including a calcium carbonate-containing
cement. High levels of graft slippage within the bone tunnels
were observed during cyclical loading, showing the bone
cement to be unsuitable as a primary ﬁxation method.
Ad i ﬀerent injectable material was proposed by Ishikawa
et al. [35]. Collagen gels containing HA for the improvement
of tendon-bone healing were tested in a rabbit model. A
directbondwasshowntobeformedbetweenthetendonand
the bone in the presence of the gel, which contained 60% HA
and 40% collagen. The HA particles were up to 200μmi n
size.ThepresenceofboththecollagenandtheHAresultedin
collagen ﬁbres from the tendon being interwoven into newly
formed bone around the graft. In the controls, in which no
gel was applied, amorphous tissue formed in the tendon-
bone interface. The eﬀect of the improved interface on the
mechanical performance of the graft was not assessed.
3.2.2. Bone Screws in ACL Reconstruction. A further means
of introducing CaP into the bone tunnel is to include them
in the material to be used in the ﬁxation of the graft. This
commonly involves the use of resorbable ﬁxation screws
containing CaP. A number of studies have examined the
use of CaP-containing interference screws for soft tissue
graft ﬁxation. Hunt et al. compared bone tunnel healing for
graftsﬁxedwithcommerciallyavailablePLLA-HAcomposite
screws with that for grafts ﬁxed with simple PLLA screws
in ovine models over a period of 12 months [36]. New
bone formation along the perimeter of the screw threads
was found to be signiﬁcantly increased in screws containing
HA than those containing PLLA alone. These observed
increasesinboneingrowthandmineralisationcanbedirectly
attributed to the presence of the HA as the mechanical
ﬁxation of the two types of screw is comparable. The
mechanical properties of the ﬁxations and the phenomenon
of bone tunnel widening were not investigated.
The same composite screws (HA/PLLA) have also been
examinedinvivoinaclinicalsettingin100patients[37].The
results supported those of Hunt et al., with a reduction in
tibial tunnel widening occurring around the screw in cases
where the composite screws were used. It is interesting to
note, however, that above the screw, in the section of the
tunnel containing tendon graft, bone tunnel widening was
unaﬀected by the type of screw used. This suggests that the
eﬀect of the HA is highly localised. The improvement in
bone tunnel healing around the screw did not correspond to
any diﬀerence in clinical outcome or knee laxity. However,
this study was carried out 12 months after surgery. More
diﬀerences between the experimental and control groups
m a yb e c o m ea p p a r e n ta tl a t e rt i m ep o i n t s .
3.2.3. Precipitation of CaP. In contrast with other methods
which seek to apply CaP in the bone tunnel or include it
in the ﬁxation, Mutsuzaki et al. deposited a layer of CaP
directly onto a tendon graft [23, 38]. This was achieved by
soaking the ends of the tendon in Ca-containing solution
and a PO4-containing solution in turns for 30 seconds each.
The complete soaking process took ten minutes, and the CaP
layer deposited was over 100μm thick. XRD analysis showed
the deposited material to be made up of low-crystallinity
apatite and dicalcium phosphate dihydrate. The deposited
CaP was examined by transmission electron microscopy and
was shown to be made up of needle-like crystals formed on
and between the collagen ﬁbrils of the tendon [23].
When implanted in white rabbits, the “hybridized”
tendons appeared to heal faster than controls which had
been soaked only in saline. As early as 5 days after
surgery, increased numbers of osteoclasts and osteoblasts
were observed in the experimental tendons compared to the
controls. Over a period of four weeks, tendon-bone healing
was more advanced in the healing group, particularly in the
formation of a direct tendon-bone bond, without the layer
of interfacial ﬁbrous tissue observed in the controls [38].
Although the later study implanting hybridized tendons in
goatsfailedtoﬁndacorrespondingincreaseinUTSsixweeks
aftersurgery,aslightchangeinthefailuremodewasobserved
between experimental grafts and controls [23]. Failures in6 Journal of Tissue Engineering
theCaPtreatedgraftsoccurredintheintra-articularportion,
whereas three of the seven control grafts failed by pullout
from the bone tunnel. The authors claim that this implies
that the ﬁxation in the CaP grafts is stronger than that in
the controls and may be related to the earlier observation
of improved bone tunnel healing; however, the assessment
is not statistically signiﬁcant. The studies were carried out six
weeks after implantation.
In addition to studies directly investigating bone tunnel
healing, CaPs have been used for enhancement of the
attachment of other soft tissues grafts to bone. The following
section presents the outcomes of investigations into these
applications of CaP-based materials.
3.2.4. Calcium Phosphates in Other Relevant Applications.
The use of porous CaP blocks has been suggested as a
means of attaching tendon to bone. Although their study
w a sn o tb a s e do na nA C Lr e p l a c e m e n tp r o c e d u r e ,O m a e
et al. examined healing between two types of porous CaP
and tendon grafts implanted with them in rabbit femora
[24]. The two materials tested were both commercially
available in Japan. The ﬁrst had a pore size around 150μm,
was 72%–78% porous and was made up predominantly
of interconnected pores. The second material had a pore
size of 50–300μm and 35%–48% porosity with a lower
level of pore interconnection. Wedges or cylinders of the
CaP were implanted in the bone with cylindrical holes
allowing the tendon graft to be passed through the block.
The material with the interconnected porosity induced the
best healing, with early formation of collagenous tissue
followed by bone ingrowth into the material. Twenty-four
weeks after surgery the tendon was found to be in direct
contact with the bone grown into the CaP material. The
amount of biological ingrowth into the other material was
f o u n dt ob el o w e r .T h i sw a sap r e d i c t a b l eo u t c o m ed u et o
the lack of interconnectivity in the porous material. The
improved ingrowth in the interconnected material resulted
in an increase in tendon pullout strength. This paper does
not, however, comment extensively on the healing between
the CaP and the tendon, focussing instead on the extent of
bone ingrowth into the porous material. An extension to
this study found that seeding bone marrow stromal cells into
the interconnected CaP ceramics further improved bone
attachment [39]. This procedure could be considered a step
towards replicating a BTB graft by artiﬁcial means.
CaP is also used as a synthetic bone graft and has been
proposed for use in a variety of forms as a scaﬀold com-
ponent for tissue engineering. Some of these applications
may be transferable to ACL graft ﬁxation, particularly in the
development of artiﬁcial grafts. The following brief review
summarises investigations of CaP which may be relevant or
applicable to ACL graft development.
Al Munajjed and O’Brien produced collagen scaﬀolds
and coated them in precipitated hydroxyapatite by serial
soaking in calcium chloride and ammonium sodium hydro-
gen phosphate solutions [46]. The scaﬀolds produced were
not suﬃciently strong for implantation in bone without
support, having a compressive modulus of 10.3KPa. How-
ever, this material combination may have applications in
bonetunnels,particularlyifthecollagen-CaPstructurecould
be tailored to encourage regrowth of a gradual structure
mimicking the natural ACL insertion.
Mavis and Demirtas used a simulated body ﬂuid-like
solution to deposit nanoscale HA particles on polycaprolac-
tone nanoﬁbres. The aggregation of the HA did not compro-
mise the porosity of the resulting scaﬀold. The presence of
HA was shown to increase the attachment and proliferation
of osteoblast-like (MC3T3) cells on the scaﬀolds in vitro
[47]. Other HA-containing polymer composites proposed
forbonetissueengineeringincludeHA-Poly(esterurethane),
which was shown to retain its viscoelastic properties and
biocompatibility after HA incorporation [48] and HA-
polyamide [49].
The development of synthetic materials for the replace-
ment of articular cartilage has advanced in recent years.
The production of compliant materials which mimic more
closely the properties of natural cartilage necessitates the
development of a means of ﬁxing the graft to the underlying
bone. As suggested by Sinha and Guha, the incorporation
of HA into an appropriate scaﬀold material may facilitate
ﬁxation to bone tissue [50]. In this study, HA-PVA hydrogels
were obtained via the freeze-thawing of a PVA emulsion
in which HA particles had been made to precipitate. The
resultingscaﬀoldswereporousandtheauthorssuggestthatit
maybepossibletoinduceagradientintheHAconcentration
through the structure, making it suitable for bone-cartilage
tissue engineering [50]. Similarly, Wu et al. investigated
a PVA hydrogel for cartilage replacement [51]. The HA
particles were found to increase elastic modulus of the
material. In vitro, the presence of HA also increased apatite
formation when submerged in simulated body ﬂuid. This is
often interpreted as a sign of bioactivity and is a commonly
observed phenomenon in HA-containing materials [52].
These promising in vitro indications are complemented
by a further study which included an in vivo evaluation.A n
HA-PVA hydrogel construct with a graduated HA content
was fabricated by a sol-gel method by Zheng et al. and
tested both in vitro and in vivo [53]. PVA does not usually
adhere to cartilage and living bone. After immersion in
SBF, only HA-containing materials were coated in a bio-
mineralised CaP layer. This corresponded to good bonding
and osteoid development between the subchondral bone
and the synthetic material when implanted in the femoral
heads of rabbits. The authors considered HA-PVA to be
a promising articular cartilage construct, particularly with
respect to its bone integration.
The addition of HA to PVA in order to improve cell
attachmentpropertieswasalsoputforwardbyDegirmenbasi
et al. [54] for use in articular cartilage replacement. The
HA/PVA/collagen scaﬀolds produced were porous, a feature
desirable for the encouragement of bone ingrowth. However,
the pores produced measured no more than 500nm, a
dimension too small to allow bone ingrowth to occur [55].
An alternative approach to improving PVA attachment
to bone in cartilage repair is to coat the hydrogel attachment
surfacewithalayerofamorphousHAtoprovideaninterface.
One study coated the bone-contacting surfaces of a PVA
hydrogel construct with amorphous HA using pulsed laserJournal of Tissue Engineering 7
Table 2: Mechanical testing of various augmentation methods for bone tunnel healing. For ease of comparison and where available, data
from mechanical testing at six weeks after surgery are given. Results at earlier and later time points are detailed in the text. Where six week
data is not available, the nearest time period is included. aThese values were calculated from the average values in the preceding two columns.
bReﬂects a diﬀerence in the predominant mode of failure from pullout failure in the controls to midsubstance failure in the treated subjects.
Augmentation method
Average increase in
strength (as % of
control)a
Ultimate tensile
strength in treated
group (N)
Ultimate tensile
strength in control
group (N)
Change in mode
of failureb Time (weeks) Reference
GCSF 114% 99.45±25.5 31.97±11.9  4[ 40]
BMP-2 (low dose) 0% 142±50 143±68  4[ 41]
BMP-2 (high dose) Not statistically
signiﬁcant 210±66 171±20  4[ 41]
BMP-7 77% 380±33 215±44  6[ 42]
Xenograft-derived
BMP 52% 64.71±21.36 42.69±15.03 × 6[ 43]
Stem cells 122% 55.7 (Range 21–90) 30.6 (Range 18–43) × 4[ 44]
Periosteum 43% 46.9±13.3N/mm 32.7±13.3N/mm  6[ 3]
Periosteum 77% 57.1±16.7 32.23±9.9
2/10 failed by pullout
in treated group, 1/10
in control
6[ 45]
Periosteum with
bone marrow
Not statistically
signiﬁcant 35.39±9.3 32.23±9.9
3/10 failed by pullout
in treated group, 1/10
in control
6[ 45]
deposition (PLD) [56]. This technique has the advantage of
allowing targeted deposition which, unlike soaking methods,
leaves the articular surface of the PVA clear of HA. When
tested in vitro, the presence of the 300nm thick layer of
HA greatly increased the attachment and proliferation of
murine ﬁbroblasts (L929). The investigation was continued
with a study of osteoblast cell (MC3T3) attachment to
HA-covered gels [57]. Cell numbers were higher on the
HA than on the hydrogels alone, as were both alkaline
phosphatase and osteocalcin production. The presence of
the HA encouraged osteoblast diﬀerentiation. The authors
consider this an indication that HA coating by PLD is an
eﬀective way of ﬁxing PVA hydrogels to bone.
A recent review considered the range of materials
applied for the enhancement of intra-tunnel healing [2].
The following section brieﬂy presents these strategies for
theaugmentationACLgraftincorporationbeforecomparing
their results with those found for CaPs. Table 2 summarises
the eﬀects on ﬁxation strengths documented for some of the
diﬀerent methods.
4. AlternativeAugmentationMaterials
4.1. Soft Tissue Grafts
4.1.1. Biologics. The use of artiﬁcial or processed bone
proteins and growth factors to augment healing in ACL
replacementgraftshasbeeninvestigated.Granulocytecolony
stimulating factor (GCSF) causes the production of granulo-
cytes and stem cells in bone marrow. It has been shown to
inducethediﬀerentiationofneutrophils(cellsoftheimmune
system associated with inﬂammation) and to encourage
angiogenesis and the diﬀerentiation and migration of mes-
enchymal stem cells. Sasaki et al. therefore proposed that the
application of GCSF may encourage accelerated bone tunnel
healing. GCSF was incorporated into a gelatin hydrogel to
control its release and applied during ACL reconstruction
in adult beagle dogs. In biomechanical tests, the treatment
resulted in a large increase in the failure load (see Table 2).
Histological investigations also indicated accelerated bone
development around the GCSF treated grafts [40]. The
majority of experimental grafts failed midsubstance while
untreated grafts failed by pullout, indicating an increase in
the bone-graft interface.
Bone morphogenetic proteins (BMPs) are signalling
proteins that inﬂuence tissue structures in the body. They
have been shown to have a role in skeletal development. Both
BMP-2 [58]a n dB M P - 7[ 42] have been shown to increase
graft ﬁxation strengths when applied in the bone tunnels
in animal models. Likewise, BMP-7 was shown to increase
the volume of bone formed within the tunnels six weeks
after implantation [42]. However, one study found that the
diﬀerence in strength between grafts treated with BMP-2
and controls diminished over time (as measured eight weeks
after surgery) [41]. This implies that these products induce
faster healing, but not necessarily stronger ﬁxations in the
long-term.
Chen et al. advanced the study of the use of BMPs by
combining them with implanted periosteal progenitor cells
[4]. The protein was tested in soluble form (BMP-2 alone)
and tethered to the surface to prevent dissipation (BMP-
2 tethered with hyaluronic acid). At three and six weeks
after surgery, more calcium and collagen were found in the
soluble BMP-2-containing samples than in controls, with
signiﬁcantly increased amounts identiﬁed in the hyaluronic-
acid tethered samples. At three weeks after surgery, the
mode of failure was changed in the hyaluronic-tethered
BMP-2 group, in which no samples failed by tibial pullout.8 Journal of Tissue Engineering
Failure strengths were higher in the treated groups than
in the control, with the hyaluronic-acid tethered grafts the
strongest six weeks after surgery. Similar results to those
found for BMPs were observed after application of a bone-
derived extract (Bone Protein, Sulzer Orthopaedics) [59]. In
tensile tests, failure loads were signiﬁcantly higher than in
control groups at two, four and eight weeks after surgery,
although the failure modes were unchanged.
Bone samples can be used as a source of natural BMPs.
Pan et al. studied the eﬀect of applying recombined bone
xenograft within the bone tunnels after ACL replacement
[43]. The xenograft was used to produce BMPs, which
were then mixed with cancellous bone and formed into
cylinders which were attached to the ends of tendon grafts
and implanted in the tibial and femoral bone tunnels in
rabbitmodels.Theaverageloadtofailureofthetreatedgrafts
at this time point was 58% greater than that of the controls.
Failure strength at 12 weeks after surgery was also increased.
Demineralised bone matrix (DBM) is a further source of
BMPs which has been proposed as a means of enhancing
tendon-bone healing in rotator cuﬀ repair. Application of
this material has been shown to increase ﬁxation strengths
between tendon and bone in an ovine patellar model. The
presence of the DBM induced an increase in the growth of
ﬁbrocartilage and mineralised ﬁbrocartilage at the tendon-
bone interface [60].
These studies demonstrate the importance of the mode
of delivery chosen for these proteins, as shown by the
diﬀerences in results between tethered and nontethered
molecules. Longer studies would be beneﬁcial in order to
properly evaluate their eﬃcacy. BMPs have been applied
in other bone repair applications, producing promising
results, and BMP-containing products have been approved
by regulatory bodies. The reader is referred to a recent review
for further information [61].
4.1.2. Cells. As well as the use of biologics (which include
BMPs and GCSF), the application of materials seeded with
mesenchymal stem cells (MSCs), from which osteoblasts are
derived, has also been shown to increase failure strengths
and improve bone tunnel healing. In one such study,
MSCs were applied to the surface of a graft, seeded in a
ﬁbrin glue carrier. The diﬀerence in strength between the
experimental and control groups was shown to increase over
time after application of these cells up to eight weeks after
surgery. This trend is in contrast with those observed for
other interface healing enhancement materials. Histological
examination showed the presence of type II collagen at the
tendon-bone interface eight weeks after surgery. Histological
characteristics of the interface were found to be similar to
normal rabbit ACL insertions [44]. The development of
insertion architecture comparable to that of the native ACL
is desirable if it results in comparable strengths and loading
responses in the graft.
4.1.3. Periosteum. The augmentation of intra-tunnel sec-
tions using periosteum has been proposed due to the
osteogenic potential of periosteal cells and tissue. A number
of studies [2, 62, 63] have found improvements in intra-
tunnel bone development and an increase in mean load to
failure using this technique. A further study found that while
the periosteum treated grafts displayed higher strength than
thecontrolgraftstreatedsixweeksaftersurgery(seeTable 2),
the diﬀerence at 12 weeks was not statistically signiﬁcant.
An additional group of grafts in this study were treated
with bone marrow in addition to periosteum. No statistically
signiﬁcant diﬀerence was observed in ﬁxation strength six
weeks after surgery. However, at 12 weeks an increase of 47%
was observed [45].
The harvesting process for periosteal tissue is fast,
requiring only three additional minutes of surgery [62]. In
animalmodels,theadditionperiostealtissuetotendongrafts
provided increased strength and resulted in a change of
failure mode compared to controls [3]. This technique has
the advantage of delivering autologous bone-forming cells
to the bone tunnel. It is also possible that the presence of
the layer of periosteal tissue in the tunnel provides some
mechanical beneﬁt in limiting the movement of the graft
within the tunnel.
Tendon grafts remain the “gold standard” in ACL
replacement, despite various artiﬁcial grafts which have been
proposed over the last thirty years. Although ultimately
these artiﬁcial grafts were not considered successful, useful
information may still be obtained from attempts to encour-
age long term ﬁxation by improving bone healing around
them. The following section reviews additional means for
improving graft ﬁxation that has been employed when
implanting artiﬁcial ACL grafts.
4.2. Artiﬁcial Grafts. Prosthetic grafts for ACL replacement
havebeenavailablesincethe1970s.Examplesofthematerials
used for these devices include carbon, Gore-Tex, Dacron,
polypropylene, and polyethylene terephthalate (PET). Gen-
erally, outcomes of these devices have been poor, leading
to the withdrawal from the market of the vast majority
of artiﬁcial grafts. Failure modes for artiﬁcial grafts have
included intra-articular rupture, foreign body reactions and
loosening,abrasionatthebonetunnelexit,failureofﬁxation
and poor intratunnel healing [12]. Abrasion at the bone
tunnel exit has been shown to be signiﬁcantly reduced by
chamfering of the corners of the bone around the tunnel [1].
Anumber ofstudies haveconsideredthepromotion ofintra-
tunnel healing in artiﬁcial grafts. For example, the Leeds-
Keio ligament, a polyester mesh intended to act as a scaﬀold
for soft tissue repair, was ﬁxed in place using bone plugs,
replicating the BTB type autografts [12].
Following disappointing outcomes for artiﬁcial grafts
due to wear and abrasion, the inclusion of biological
components to allow for graft remodelling has been the
subject of several papers. In the native ACL, the primary
zones of the natural ligament-bone insertion structure (lig-
ament, ﬁbrocartilage, mineralised ﬁbrocartilage, and bone)
are populated by diﬀerent cell types. Spalazzi et al. recently
developed a three-phase scaﬀold designed to mimic this
interface [64]. This single structure was made up of a
poly(lactic-co-glycolic acid) (PLGA) mesh for ﬁbroblast and
soft tissue culture, PLGA microspheres for the transitionJournal of Tissue Engineering 9
zone and sintered PLGA and bioactive glass for the bone
section. The device is suggested for use as a graft collar in
ligament grafts. It has been shown to support the growth
of multiple cell types (seeded in vitro) when implanted
subcutaneously in an animal model but is yet to be tested
functionally.
Chitin is a biopolymer found in the exoskeletons of
crustaceans and insects. It is considered to be a bioactive
material. One study proposed the application of chitin as a
means of improving the attachment of artiﬁcial ligaments.
This in vivo study in a rat model showed that the application
of chitin/chitosan to a polyester fabric signiﬁcantly increases
pullout strength and bone formation in the short term
[65]. The pullout strength of the treated samples was found
to be twice that of the nontreated polyester controls two
weeks after implantation. The advanced bone growth is
attributed by the authors to the bioactivity of chitosan,
including its ability to promote osteoblast attachment and
extracellular matrix production. However, images of the
coated and control materials also demonstrate that coating
the fabric signiﬁcantly increases the surface area available
for cell attachment and this may also play a role in the
advancement of bone formation.
A study of bone ingrowth into Gore-Tex PTFE artiﬁcial
ligaments suggested that the porosity of the graft ﬁbres,
which were 75% air by volume, was key to allowing bone
ingrowth. This suggests that the provision of porosity for tis-
sue ingrowth at the bone-graft interface should therefore be
considered important when applying bulk materials within
the bone tunnel. A stable ﬁxation was found within the bone
tunnels up to 18 months after implantation in an ovine
model [66]. However, these ligaments were later removed
from the market due to problems including loosening and
synovitis, along with two documented cases of osteolysis
[67]. The implications of these ﬁndings as well as those for
CaP based materials are considered in the discussion section.
5. Discussion
5.1. Test Methodologies. Diﬀerences in methodology render
direct quantitative comparisons between these studies com-
plex. Results of biomechanical testing may be inﬂuenced
by rates of extension, clamping of samples, and chosen
angles of ﬂexion. These are not standardised across the
testing included in this review. The type of animals used
is inconsistent, with rabbit, porcine, and canine models all
being common. The number of subjects also varies in animal
tests [23, 41].
Time periods for mechanical testing range from two
weeks to 52 weeks. The majority of studies last between six
and 12 weeks. As the graft healing progresses, diﬀerences
between treated groups and controls tend to change and do
not always follow predictable patterns. Although diﬀerences
are visible at 6 weeks and sometimes earlier, this may not be
apredictorofincreasedstrengthlater,asshownbytheresults
of Wen et al. [32].
A change in failure mode may be considered a simple
means by which to measure at what point the bone tunnel
ceases to be the weakest point in the graft. The change
in failure mode in biomechanical testing may be therefore
considered a useful indicator of improvement over control
procedures. It should be noted, however, that if the graft
material degrades over time, the mode of failure may
change even if the ﬁxation strength has not increased.
Examination of failed grafts for assessment of degradation
is not commonly carried out.
The extent to which the observed improvements in
animal models may relate to changes in outcome for the
patient is unclear. Clinical studies regarding this type of
application of CaPs are rare. The use of CaPs in resorbable
screws, for example, produced improved results in animal
models but did not induce a clear improvement in outcome
for patients.
5.2. CaPs for Bone Tunnel Healing. Broadly, many of these
strategies for the augmentation of bone tunnel healing in
soft tissue grafts have been shown to have promising eﬀects.
All of the CaP-based materials were judged to have induced
improvements in the biological structures forming in the
bone tunnels during healing. The improvements included
increases in bone mass and changes in the nature of the
tissue forming in the tunnels. In the majority of cases, UTS
increased (see Table 1), suggesting that the application of
these materials increases ﬁxation strength in the short to
midterm. However, increases in ﬁxation strength do not
always introduce a change in failure mode compared to that
observed in the controls. Longer-term studies are desirable
in order to properly assess increases in ﬁxation strength in
ACL grafting and to provide more detailed information for
the planning of clinical trials, through which the beneﬁts of
these treatments to the patient may be assessed.
With respect to both increases in ﬁxation strength and
changing the mode of failure, the application of CaPs has
been shown to produce results comparable to, and in some
cases better than, those obtained using materials whose
application is more challenging (see Table 2).
When considering which technique to apply for the
improvement of intratunnel bone healing, it is important
to evaluate the complexity and cost of the method with
respect to its eﬃcacy in improving ﬁxation. In the future,
the development of devices facilitating the application of
GCSF or mesenchymal stem cells, both of which have been
shown to produce signiﬁcant improvements in strength, may
be desirable. However, for immediate improvement in bone
tunnel healing, the application of existing CaP products such
as bone cement seems to signiﬁcantly improve ﬁxation at a
low cost and using a simple procedure and existing approved
materials. CaP-based materials were shown to increase
ﬁxation strengths and advance healing at the tendon-bone
interface.Theyarewidelyusedbiomaterialswhicharesimple
to apply and are likely to be among the least expensive of the
proposed methods. They have a long-standing safety record
and Good Manufacturing Practices (GMP) for them are well
established.
The improvements in bone tunnel healing in ACL grafts
ﬁxed using CaP is usually attributed to their chemical
composition. Bone mineral is a nonstoichiometric form
of CaP containing additional elements such as silicon and10 Journal of Tissue Engineering
magnesium. Although the exact properties of CaPs depend
on the manufacturing processes used to obtain them, they
are generally considered to be bioactive. There is insuﬃcient
evidence to show whether any particular phase of CaP is
preferable in this application.
In addition to the changes in the chemical environment
around the healing interface, the application of CaP in
injectable or bulk form may oﬀer mechanical advantages
in ACL graft ﬁxation. In order for tendon-bone interfacial
healing to occur, movement between the two faces must be
limited. Where an extensible graft, such as a tendon graft, is
insertedintothebonetunnel,theapplicationofbonecement
orporousblocksmayprovideadditionalﬁxationproximalto
the joint space, limiting intratunnel movement of the graft
and facilitating healing. The improvement of bone tunnel
healing in this manner may also limit abrasion and wear of
the graft due to the restriction of intratunnel graft motion.
While CaP-containing screws are commercially available
and clinical evaluation is possible, the application of CaP
cement in the bone tunnels does not appear to have been the
subjectofaclinicalstudy.In vitro studiesoftheapplicationof
CaP cements in the bone tunnel have shown signiﬁcant and
consistent improvements in ﬁxation strength and healing of
bone tissue in and around the tunnels. This technique could
be simply applied and merits further examination.
5.3. Application to Artiﬁcial Graft Materials. For the attach-
mentoffutureartiﬁcialgrafts,techniquesproposedforusein
biological grafts may also be of use. Artiﬁcial grafts oﬀer the
advantage of being able to design both the graft material and
the bone-graft interface. Materials which are chosen for their
ligament-likepropertiesmaybeadaptedforboneattachment
by the application of CaP-based materials. The combination
of CaP with PVA, a material which usually resists cell
attachment, has been shown to improve its attachment to
bone. These techniques for combining polymeric materials
with CaP could be adapted to improve the attachment of an
artiﬁcial ACL graft.
6. Conclusions
This review examines the hypothesis that the application of
CaP can improve bone tunnel healing after ACL replace-
ment. In general, ACL-bone tunnel ﬁxation strength can be
increased by approximately 100% through the incorporation
of CaP and other techniques. The application of growth
factors and stem cells merits further investigation but is not
immediately clinically applicable. The use of commercially
available CaP cements induced changes in all the major
indicators: bone formation, biomechanical strength, and
mode of failure in biomechanical testing. While the evidence
is not conclusive, it suggests that CaP materials perform as
well as more complex biologic or cell-based solutions in this
application. Studies show that the presence of CaP induces
improvements in healing as investigated using histology and
medical imaging as well as increases in strength and changes
in mode of failure in mechanical testing.
A clinical study into its use to augment ﬁxation and bone
tunnel healing in ACL grafts is merited. More speciﬁcally,
a study linking experimental ﬁxation strengths in a suitable
animal model to clinical outcomes in human subjects would
be of great beneﬁt, both in establishing the eﬃcacy of this
treatment and in helping to establish what parallels, if any,
can be drawn between biomechanical testing in animals and
clinical results.
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